BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 34755388)

  • 1. A group-sequential randomized trial design utilizing supplemental trial data.
    Kotalik A; Vock DM; Hobbs BP; Koopmeiners JS
    Stat Med; 2022 Feb; 41(4):698-718. PubMed ID: 34755388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical appraisal of Bayesian dynamic borrowing from an imperfectly commensurate historical control.
    Harun N; Liu C; Kim MO
    Pharm Stat; 2020 Sep; 19(5):613-625. PubMed ID: 32185886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Bayesian group sequential design for randomized biosimilar clinical trials with adaptive information borrowing from historical data.
    Zhang W; Pan Z; Yuan Y
    J Biopharm Stat; 2022 May; 32(3):359-372. PubMed ID: 35679137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian group sequential designs for phase III emergency medicine trials: a case study using the PARAMEDIC2 trial.
    Ryan EG; Stallard N; Lall R; Ji C; Perkins GD; Gates S
    Trials; 2020 Jan; 21(1):84. PubMed ID: 31937351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal timing for an accelerated interim futility analysis incorporating real world data.
    Haine LMF; Murray TA; Koopmeiners JS
    Contemp Clin Trials; 2024 May; 140():107489. PubMed ID: 38461938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bayesian basket trial design with false-discovery rate control.
    Zabor EC; Kane MJ; Roychoudhury S; Nie L; Hobbs BP
    Clin Trials; 2022 Jun; 19(3):297-306. PubMed ID: 35128970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Bayesian platform trial design with hybrid control based on multisource exchangeability modelling.
    Wei W; Blaha O; Esserman D; Zelterman D; Kane M; Liu R; Lin J
    Stat Med; 2024 May; 43(12):2439-2451. PubMed ID: 38594809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simulating and reporting frequentist operating characteristics of clinical trials that borrow external information: Towards a fair comparison in case of one-arm and hybrid control two-arm trials.
    Kopp-Schneider A; Wiesenfarth M; Held L; Calderazzo S
    Pharm Stat; 2024; 23(1):4-19. PubMed ID: 37632266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal sample size determination for single-arm trials in pediatric and rare populations with Bayesian borrowing.
    Ji Z; Lin J; Lin J
    J Biopharm Stat; 2022 Jul; 32(4):529-546. PubMed ID: 35604836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adaptive designs in critical care trials: a simulation study.
    Li W; Cornelius V; Finfer S; Venkatesh B; Billot L
    BMC Med Res Methodol; 2023 Oct; 23(1):236. PubMed ID: 37853343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bayesian adaptive design for pediatric clinical trials incorporating a community of prior beliefs.
    Wang Y; Travis J; Gajewski B
    BMC Med Res Methodol; 2022 Apr; 22(1):118. PubMed ID: 35448963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calibrated dynamic borrowing using capping priors.
    Ling SX; Hobbs BP; Kaizer AM; Koopmeiners JS
    J Biopharm Stat; 2021 Nov; 31(6):852-867. PubMed ID: 35129422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian hypothesis testing with frequentist characteristics in clinical trials.
    Quan H; Zhang B; Lan Y; Luo X; Chen X
    Contemp Clin Trials; 2019 Dec; 87():105858. PubMed ID: 31669448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of Bayesian information borrowing methods in basket trials and a novel proposal of modified exchangeability-nonexchangeability method.
    Daniells L; Mozgunov P; Bedding A; Jaki T
    Stat Med; 2023 Oct; 42(24):4392-4417. PubMed ID: 37614070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bayesian clinical trial design using historical data that inform the treatment effect.
    Psioda MA; Ibrahim JG
    Biostatistics; 2019 Jul; 20(3):400-415. PubMed ID: 29547966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incorporating historical two-arm data in clinical trials with binary outcome: A practical approach.
    Feißt M; Krisam J; Kieser M
    Pharm Stat; 2020 Sep; 19(5):662-678. PubMed ID: 32227680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using Bayesian adaptive designs to improve phase III trials: a respiratory care example.
    Ryan EG; Bruce J; Metcalfe AJ; Stallard N; Lamb SE; Viele K; Young D; Gates S
    BMC Med Res Methodol; 2019 May; 19(1):99. PubMed ID: 31088354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Bayesian and frequentist group-sequential clinical trial designs.
    Stallard N; Todd S; Ryan EG; Gates S
    BMC Med Res Methodol; 2020 Jan; 20(1):4. PubMed ID: 31910813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Study of Bayesian Information Borrowing Methods in Oncology Clinical Trials.
    Su L; Chen X; Zhang J; Yan F
    JCO Precis Oncol; 2022 Mar; 6():e2100394. PubMed ID: 35263169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Bayesian Hybrid Adaptive Randomisation Design for Clinical Trials with Survival Outcomes.
    Moatti M; Chevret S; Zohar S; Rosenberger WF
    Methods Inf Med; 2016; 55(1):4-13. PubMed ID: 26404511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.